<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Review ArticleInternational Journal of Basic & Clinical Pharmacology

Publication:
A review on pregabalin for the treatment of painful diabetic peripheral neuropathy

Int J Basic Clin Pharmacol. 2017;6(9):2105-2110.DOI10.18203/2319-2003.ijbcp20173652

Thumbnail Image
View on the journal's website(opens in a new tab)

Abstract

Pregabalin is an anti-epileptic drug which has been used for the treatment of diabetic peripheral neuropathy. Earlier, it was more prescribed as an adjuvant therapy for treating the partial seizures with or without secondary generalization in adults. It is an antagonist of voltage sensitive calcium ion channel on the presynaptic neuron. Pregabalin has a very good pharmacokinetic profile, possesses linear pharmacokinetics with low inter-variability of subjects. It does not show protein binding and does not interfere with the metabolism of other drugs because pregabalin undergoes very less metabolism. This factor has confirmedly shown that its benefits outweigh the risk. Different clinical trials and case reports have confirmed the fact that is reduces the pain involved in peripheral neuropathy. Though, more drugs have come like tricyclic antidepressant to manage the pain but due to their adverse effects, they are less used. This reappraisal is all about the pregabalin, its role, and where it stands among other drugs for management of pain aassociaed with diabetic peripheral neuropathy.

Keywords

Affiliations

  1. Department of Pharmacology, Pranveer Singh Institute of Technology, Kanpur, Uttar Pradesh, India
  2. Department of Pharmacy, Subharti College of Pharmacy, Meerut, Uttar Pradesh, India
  3. Department of Pharmacy, Lloyd Group of Institutions, Greater Noida, Uttar Pradesh, India

Full item record